Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations

American Journal of Hypertension

Volumn 28, Issue 3, 2015, Pages 355-361

  Achelrod, Dmitrij ^a   Wenzel, Ulrich ^b   Frey, Simon ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Blood pressure; Epidemiology; Hypertension; Meta analysis; Prevalence; Refractory hypertension; Resistant hypertension

Indexed keywords

DATA EXTRACTION; DATA SYNTHESIS; HUMAN; INTERVENTION STUDY; META ANALYSIS; MORBIDITY; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; SENSITIVITY ANALYSIS; SEX; SYSTEMATIC REVIEW; HYPERTENSION; TREATMENT FAILURE;

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; OBSERVATIONAL STUDY AS TOPIC; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 84929253215     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu151     Document Type: Review

References (46)

1. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med 2011; 17:1402-1409.
2. Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ 2012; 345:e7473-e7473.
3. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, Caldarella MP, Neri M, Cuccurullo F, Mezzetti A. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18:1422-1428.
4. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103-111.
5. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393-401.
6. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk H-D, Stocker H, Mler P, Jennings GT, Wagner F, Bachmann MF. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebocontrolled phase IIa study. Lancet 2008; 371:821-827.
7. Garber AM. An uncertain future for cardiovascular drug development N Engl J Med 2009; 360:1169-1171.
8. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011; 58:1008-1013.
9. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahl B, Poulter NR. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011; 29:2004-2013.
10. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
11. Loney PL, Chambers LW, Bennett KJ, Roberts JG, Stratford PW. Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Can 1998; 19:170-176.
12. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: Wiley: 2009.
13. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14:7-12.
14. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant Am J Hypertens 2001; 14:1263-1269.
15. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393-404.
16. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
17. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
18. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013; 62:691-697.
19. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18:619-626.
20. Gee ME, Bienek A, McAlister FA, Robitaille C, Joffres M, Tremblay MS, Johansen H, Campbell NRC. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol 2012; 28:375-382.
21. Holecki M, Duawa J, Chudek J. Resistant hypertension in visceral obesity. Eur J Intern Med 2012; 23:643-648.
22. Julius S. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16:544-548.
23. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL, REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013; 34:1204-1214.
24. Leotta G, Rabbia F, CanadA, Testa E, Papotti G, Mulatero P, Veglio F. Characteristics of the patients referred to a hypertension unit between 1989 and 2003. J Hum Hypertens 2008; 22:119-121.
25. Massierer D, Oliveira ACT, Steinhorst AM, Gus M, Ascoli AM, Gonlves SC, Moreira LB, Correa V Jr, Nunes G, Fuchs SC, Fuchs FD. Prevalence of resistant hypertension in non-elderly adults: prospective study in a clinical setting. Arquivos Brasileiros de Cardiologia 2012;99: 630-635.
26. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Therapeut 2009; 31:1116-1123.
27. Mezzetti A, Pierdomenico SD, Costantini F, Romano F, Bucci A, Di Gioacchino M, Cuccurullo F. White-coat resistant hypertension. Am J Hypertens 1997; 10:1302-1307.
28. Muxfeldt ES, Nogueira ADR, Salles GF, Bloch KV. Demographic and clinical characteristics of hypertensive patients in the internal medicine outpatient clinic of a university hospital in Rio de Janeiro. Revista Paulista de Medicina 2004; 122:87-93.
29. Otero FR, Grigorian LS, Lado ML, Lado AL, Turrado VT, Santos JAR, Pazo CP, Vquez JAM, Vaamonde LM, Gonzez JRJ, Grupo Barbanza. [Association between refractory hypertension and cardiometabolic risk. The HIPERFRE study]. Nefrologiá 2008; 28:425-432.
30. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
31. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
32. Rosenbaum D, Villeneuve F, Gury C, Girerd X. [Frequency of hypertension resistant to treatment and indication for renal denervation.]. Annales de Cardiologie et d'Angeiologie 2012; 61:229-235.
33. Salvetti M, Muiesan ML, Paini A, Agabiti Rosei C, Aggiusti C, Bertacchini F, Stassaldi D, Beschi F, Rubagotti G, Monteduro C, Castellano M, Agabiti Rosei E. Prevalence of resistant hypertension in a general population in northern Italy: associated cardiovascular risk factors and target organ damage. Artery Research 2011; 5:151.
34. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991; 151:1786-1792.
35. Smith AC, Villarosa I., Yakovlevitch M, Bakris GL. Resistant hypertension in a tertiary care clinic: revisited. Am J Hypertens 2000; 13:A006.
36. Schmiemann G, Gebhardt K, Hummers-Pradier E, Egidi G. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25:98-103.
37. Kasiakogias A, Tsioufis K, Tsiachris D, Anastasopoulos I, Flessas D, Hatziyiannis P, Tatsis I, Leontsinis I, Tousoulis D, Stefanadis C. Prevalence, characteristics and predictive value of severe resistant hypertension for the incidence of cardiovascular disease. J Am Coll Cardiol 2012; 59:E1756.
38. Dicker D, Gavish D, Viskoper D, Leibovitz E, Yossefi C. Relationship between obesity and resistant hypertension. Am J Hypertens 2002; 15:438.
39. Gij-Conde T, Graciani A, Banegas JR. Resistant hypertension: demography and clinical characteristics in 6292 patients in a primary health care setting. Rev Esp Cardiol 2014; 67:270-276.
40. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension-its identification and epidemiology. Nat Rev Nephrol 2013; 9:51-58.
41. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125:1594-1596.
42. Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States Curr Opin Cardiol 2012; 27:386-391.
43. Hayek SS, Abdou MH, Demoss BD, Legaspi JMO, Veledar E, Deka A, Krishnan SK, Wilmot KA, Patel AD, Kumar VR, Devireddy CM. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens 2013; 26:1452-1458.
44. Alderman MH, Budner N, Cohen H, Lamport B, Ooi WL. Prevalence of drug resistant hypertension. Hypertension 1988; 11:1171-1175.
45. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62:218-225.
46. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2012; 25:514-523.